KMT2A and acute myeloid leukemia: The Tankyrase inhibitor IWR107 and IWP2G9 reduced the progression of MLL-AF9 fusion AML by interfering with Wnt–β-catenin–SIX1 signaling in THP1, MV4;11, HL60 and U937 AML cells.